Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study

被引：0
|
作者：
Abbenante, Mariachiara [1 ]
Papayannidis, Cristina [1 ]
Iacobucci, Ilaria [1 ]
Candoni, Anna [2 ]
Paolini, Stefania [1 ]
Malagola, Michele [3 ]
Emanuela, Ottaviani [1 ]
Lonetti, Annalisa [1 ]
Curti, Antonio [1 ]
Parisi, Sarah [1 ]
Testoni, Nicoletta [1 ]
Lama, Barbara [1 ]
Baccarani, Michele [1 ]
Martinelli, Giovanni [1 ]
机构：
[1] Univ Bologna, Dept Hematol Oncol Seragnoli, Bologna, Italy
[2] Div Hematol & BMT, Udine, Italy
[3] Univ Brescia, Hematol & BMT Unit, Brescia, Italy
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.4M2011-2236
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2236
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML)
    Al-Kali, Aref
    Jones, Dan
    Cortes, Jorge
    Faderl, Stefan
    Ao, Xue
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Konopleva, Marina
    Brandt, Mark
    Andreeff, Michael
    Kantarjian, Hagop
    Ravandi, Farhad
    BLOOD, 2009, 114 (22) : 820 - 821
  • [32] Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML)
    Abuasab, Tareq
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    Alvarado, Yesid
    Yilmaz, Musa
    Pemmaraju, Naveen
    Chien, Kelly S.
    Mohamed, Shehab Fareed
    Daver, Naval
    Kornblau, Steven M.
    Burger, Jan A.
    Jain, Nitin
    Islam, Rubiul
    DiNardo, Courtney D.
    Borthakur, Gautam
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2021, 138
  • [33] Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
    Hui Liu
    Rong Fu
    Lijuan Li
    Guojin Wang
    Jia Song
    Erbao Ruan
    Huaquan Wang
    Yuhong Wu
    Xiaoming Wang
    Kai Ding
    Zonghong Shao
    Clinical Drug Investigation, 2017, 37 : 167 - 174
  • [34] SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML)
    Advani, Anjali S.
    McDonough, Shannon
    Copelan, Edward
    Willman, Cheryl L.
    Mulford, Deborah A.
    List, Alan F.
    Sekeres, Mikkael A.
    Othus, Megan
    Erba, Harry P.
    Appelbaum, Frederick R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Initial Results of the Phase I/II Panobidara Study of Panobinostat in Combination with Idarubicin and Cytarabine in Patients Aged 65 Years or Older with Newly Diagnosed Acute Myeloblastic Leukaemia (AML)
    Ocio, Enrique M.
    Herrera, Pilar
    Olave, Teresa
    Brunet, Salut
    Oriol, Albert
    Martinez-Sanchez, Maria-Pilar
    Sanz, Miguel A.
    Mateos, Marta
    Aliseda, Pilar
    Winiger, Ivo J.
    Hardikar, Sushant
    Victoria Mateos, Maria
    Lopez, Javier
    San-Miguel, Jesus F.
    BLOOD, 2012, 120 (21)
  • [36] Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
    Liu, Hui
    Fu, Rong
    Li, Lijuan
    Wang, Guojin
    Song, Jia
    Ruan, Erbao
    Wang, Huaquan
    Wu, Yuhong
    Wang, Xiaoming
    Ding, Kai
    Shao, Zonghong
    CLINICAL DRUG INVESTIGATION, 2017, 37 (02) : 167 - 174
  • [37] Infectious Complications in Acute Myeloid Leukemia (AML) Patients Undergoing Induction Chemotherapy With Fludarabine/Cladribine, Cytarabine, and Idarubicin (FIA/CLIA): A Single-Center Retrospective Study
    Yohannan, Binoy
    Sharma, Akanksha
    Cervoni-Curet, Frances
    Rios, Adan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S268 - S268
  • [38] Longer Follow-Up Of The Combination Of Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy For Patients Younger Than 61 Years With Newly Diagnosed Acute Myeloid Leukemia (AML)
    Nazha, Aziz
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Huang Xuelin
    Choi, Sangbum
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautarn
    Kadia, Tapan M.
    Konopleva, Marina
    Cortes, Jorge E.
    Ferrajoli, Alessandra
    Kornblau, Steven M.
    Andreeff, Michael
    Du, Min
    Brandt, Mark
    Faderl, Stefan H.
    BLOOD, 2013, 122 (21)
  • [39] A Phase 1-2 Study of a Farnesyltransferase Inhibitor, Tipifarnib, Combined With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Jabbour, Elias
    Kantarjian, Hagop
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Verstovsek, Srdan
    O'Brien, Susan
    Faderl, Stefan
    Thomas, Deborah A.
    Wright, John J.
    Cortes, Jorge
    CANCER, 2011, 117 (06) : 1236 - 1244
  • [40] A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia
    Tsimberidou, Apostolia Maria
    Keating, Michael J.
    Jabbour, Elias J.
    Ravandi-Kashani, Farhad
    O'Brien, Susan
    Estey, Elihu
    Bekele, Neby
    Plunkett, William K., Jr.
    Kantarjian, Hagop
    Borthakur, Gautam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 395 - 400
12345